Spots Global Cancer Trial Database for Metronomic PLD in Patients With Primary Endocrine Resistant ABC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Metronomic PLD in Patients With Primary Endocrine Resistant ABC
Official Title: Efficacy and Safety of Metronomic Pegylated Liposomal Doxorubicin in Patients With Primary Endocrine Resistant Advanced Breast Cancer
Study ID: NCT03071926
Conditions
Interventions
Study Description
Brief Summary: Metronomic PLD in Patients with Primary Endocrine Resistant ABC
Detailed Description: Efficacy and Safety of Metronomic Pegylated Liposomal Doxorubicin in Patients with Primary Endocrine Resistant Advanced Breast Cancer
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Fudan University Cancer Hospital, Shanghai, , China
Contact Details
Name: Xichun Hu, MD, PhD
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
